Condition: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Sponsor: Chugai Pharmaceutical
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
This description comes directly from the study's public registry record.
Clinical trials information · only use Email · clinical-trials@chugai-pharm.co.jp
Always discuss trial participation with your own doctor first.
| University of California-Irvine | Orange, California, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Northwell Health, LLC PRIME | Lake Success, New York, United States | Withdrawn |
| Hospital for Special Surgery | New York, New York, United States | Withdrawn |
| Universtity of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Withdrawn |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| University of Pennsylvania, Perelman Center for Advanced Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| Amarillo Center for Clinical Research | Amarillo, Texas, United States | Withdrawn |
| Austin Neuromuscular Center | Austin, Texas, United States | Recruiting |
| Nerve and Muscle Center of Texas | Houston, Texas, United States | Recruiting |
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Recruiting |
+ 65 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06371417